ijms-logo

Journal Browser

Journal Browser

Special Issue "Frontiers in mTOR Signaling"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editor

Dr. Antonios N. Gargalionis
E-Mail Website
Guest Editor
Department of Biopathology, Eginition Hospital, National and Kapodistrian University of Athens, 115 28 Athens, Greece
Interests: signal transduction; mechanobiology; tumorigenesis

Special Issue Information

Dear Colleagues,

The Mechanistic Target of Rapamycin (mTOR), previously known as the mammalian target of rapamycin, is a central protein kinase that mediates the dynamic crosstalk of notable signal transduction pathways in physiology and disease. The mTOR-associated signaling cascades have been extensively investigated in the past two decades. Their fundamental role has been highlighted in several physiological processes, including cell growth and protein synthesis, metabolism and homeostasis of macromolecules, autophagy, immune, and brain function. Furthermore, deregulation of mTOR signaling networks has been well-documented in molecular mechanisms which drive carcinogenesis, diabetes, and aging. Recent findings also demonstrate that aberrant mTOR signaling is implicated in disorders of the central nervous system, including autism and Alzheimer's disease, as well as in systemic autoimmune diseases. Novel insights further suggest that mTOR regulates alterations in gut microbiota but also mediates viral survival and replication, and therefore, it plays a substantial role in regulating the host metabolic and immune functions. Regarding therapy, the mTOR inhibitors are a class of drugs that has been established as major immunosuppressants against transplant rejection, and they have been extensively tested as anticancer agents in the past with limited clinical activity. However, second-generation agents hold promise for potential efficacy in various disease entities.

In this Special Issue, we invite investigators to submit original research or review articles on the many facets in the regulation of mTOR signaling.

Dr. Antonios N. Gargalionis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mTOR signaling in cancer
  • mTOR inhibitors
  • mTOR signaling in metabolism
  • Alzheimer’s disease and mTOR signaling
  • mTOR and autophagy
  • mTOR and gut microbiota
  • mTOR and viral pathogenesis
  • mTOR and autoimmune diseases

Published Papers

This special issue is now open for submission.
Back to TopTop